ArticleNature neuroscience2020
Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.
RetractedOpen access · greenAbstract readRetracted Publication
In one paragraph
Article in Nature neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- A novel Pyroptosis-related long non-coding RNA signature for predicting the prognosis and immune landscape of head and neck squamous cell carcinoma.Cancer medicine · 2022Trial
- Feedback regulation of VISTA and Treg by TNF-α controls T cell responses in drug allergy.Allergy · 2025Article
- Integrating single cell and bulk RNA sequencing data identifies RBM17 as a novel response biomarker for immunotherapy in bladder cancer.Virchows Archiv : an international journal of pathology · 2024Article
- Cancer marker TNFRSF1A: From single‑cell heterogeneity of renal cell carcinoma to functional validation.Oncology letters · 2024Article
- Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1.Journal for immunotherapy of cancer · 2024Article
- Review
- Distinct immune escape and microenvironment between RG-like and pri-OPC-like glioma revealed by single-cell RNA-seq analysis.Frontiers of medicine · 2024Article
- Strategies to overcome low MHC-I expression in paediatric and adult tumours.Immunotherapy advances · 2024Review
- Global metabolomics study on the pathogenesis of pediatric medulloblastoma via UPLC- Q/E-MS/MS.PloS one · 2023Article
- Targeting mutant p53 stabilization for cancer therapy.Frontiers in pharmacology · 2023Review
- Tumor Necrosis Factor-Mediators of inflammation · 2023Article
- Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.Journal for immunotherapy of cancer · 2022Article
- Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.Cell death & disease · 2022Review
- Nuclear factor kappa B signaling within the rat nucleus accumbens core sex-dependently regulates cue-induced cocaine seeking and matrix metalloproteinase-9 expression.Brain, behavior, and immunity · 2022Article
- Review
- Novel necroptosis-related gene signature for predicting the prognosis of pancreatic adenocarcinoma.Aging · 2022Article
- FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoELaboratory investigation; a journal of technical methods and pathology · 2022Article
- Hypothesis: Mutations and Immunosurveillance in Obesity-Associated Colorectal Cancer.Journal of Cancer · 2022Article
- Recent Advances in Pediatric Cancer Research.Cancer research · 2021Review
- Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives.Cancers · 2021Review
Corrections and comments
- Retraction · 2021-12-14Results Not Reproducible · Unreliable Data · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
40 authors at 11 institutions in 4 countries.
Alexandra GarancherTumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Hiromichi SuzukiDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada.ORCID http://orcid.org/0000-0002-8858-0294
Svasti HaricharanTumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-4471-8853
Lianne Q ChauTumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Meher Beigi MasihiTumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Jessica M RusertTumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Paula S NorrisTumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Florent CarretteTumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Megan M RomeroDepartment of Pediatrics, Northwestern University, Chicago, IL, USA.
Sorana A MorrissyDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada.ORCID http://orcid.org/0000-0001-8526-562X
Patryk SkowronDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada.
Florence M G CavalliDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada.
Hamza FarooqDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada.
Vijay RamaswamyDivision of Haematology/Oncology and Department of Paediatrics, Hospital for Sick Children, Toronto, Canada.ORCID http://orcid.org/0000-0002-6557-895X
Steven J M JonesCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada.ORCID http://orcid.org/0000-0003-3394-2208
Richard A MooreCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada.ORCID http://orcid.org/0000-0002-0905-2742
Yussanne MaCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada.
Nina ThiessenCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada.
Yisu LiCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada.
Alaide MorcavalloDivision of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.
Lin QiBrain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Mari KogisoBrain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Yuchen DuBrain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Patricia BaxterBrain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Jacob J HendersonDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, USA.
John R CrawfordDepartments of Pediatrics and Neurosciences, University of California, San Diego - Rady Children's Hospital, San Diego, CA, USA.
Michael L LevyDepartment of Neurosurgery, University of California San Diego - Rady Children's Hospital, San Diego, CA, USA.
James M OlsonClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-5990-6534
Yoon-Jae ChoDepartment of Pediatrics, Oregon Health & Science University, Portland, OR, USA.
Aniruddha J DeshpandeTumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-5240-9356
Xiao-Nan LiBrain Tumor Program, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Louis CheslerDivision of Clinical Studies, The Institute of Cancer Research, London, United Kingdom.ORCID http://orcid.org/0000-0001-7842-2068
Marco A MarraCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada.ORCID http://orcid.org/0000-0001-7146-7175
Harald WajantDivision of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Oren J BecherDepartment of Pediatrics, Northwestern University, Chicago, IL, USA.
Linda M BradleyTumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Carl F WareTumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center and the Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Michael D TaylorDevelopmental and Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Canada.ORCID http://orcid.org/0000-0001-7009-3466
Robert J Wechsler-ReyaTumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. rwreya@sbpdiscovery.org.ORCID http://orcid.org/0000-0002-7463-8352
Sanford Burnham Prebys Medical Discovery Institute · USCanada's Michael Smith Genome Sciences Centre · CAHospital for Sick Children · CABaylor College of Medicine · USInstitute of Cancer Research · GBNorthwestern University · USOregon Health & Science University · USUniversity of California San Diego · USFred Hutch Cancer Center · USUniversitätsklinikum Würzburg · DEUniversity of Calgary · CA
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MTumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2MMouse models to discover new drivers of medulloblastomaR01CA159859 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael D. Taylor, WILLIAM A WEISS · 2011 to 2026
$10.4MVirology CoreP01CA177322 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SUN, REN · 2014 to 2018
$8.7MAnti-herpesvirus Signaling by LTalphabeta/LIGHT CytokinesR01AI048073 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI WARE, CARL F · 2001 to 2016
$7.0MMedulloblastoma and MetastasesR01CA148699 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TAYLOR, MICHAEL D., WEISS, WILLIAM A · 2010 to 2014
$2.4MCD44 Promotes Chronic Virus InfectionR21AI133280 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI BRADLEY, LINDA MAC PHERSON · 2018 to 2019
$536kA pan-cancer role for MutL loss in inducing treatment resistanceK22CA229613 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI HARICHARAN, SVASTI · 2018 to 2020
$442kCancer Research UK 14610Cancer Research UK 28278Medical Research Council MC_PC_16047Medical Research Council MC_PC_18051NCI NIH HHS K22 CA229613NCI NIH HHS P01 CA177322NCI NIH HHS P30 CA023100NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA148699NCI NIH HHS R01 CA159859NIAID NIH HHS R01 AI048073NIAID NIH HHS R21 AI133280Worldwide Cancer Research 16-1204
Abstract
Many immunotherapies act by enhancing the ability of cytotoxic T cells to kill tumor cells. Killing depends on T cell recognition of antigens presented by class I major histocompatibility complex (MHC-I) proteins on tumor cells. In this study, we showed that medulloblastomas lacking the p53 tumor suppressor do not express surface MHC-I and are therefore resistant to immune rejection. Mechanistically, this is because p53 regulates expression of the peptide transporter Tap1 and the aminopeptidase Erap1, which are required for MHC-I trafficking to the cell surface. In vitro, tumor necrosis factor (TNF) or lymphotoxin-β receptor agonist can rescue expression of Erap1, Tap1 and MHC-I on p53-mutant tumor cells. In vivo, low doses of TNF prolong survival and synergize with immune checkpoint inhibitors to promote tumor rejection. These studies identified p53 as a key regulator of immune evasion and suggest that TNF could be used to enhance sensitivity of tumors to immunotherapy.
Indexed as
AnimalsCerebellar NeoplasmsMedulloblastomaMiceMice, Inbred C57BLMice, Inbred NODMice, SCIDNeoplasm TransplantationTumor EscapeTumor Necrosis Factor-alphaTumor Suppressor Protein p53Trp53 protein, mouseTumor Necrosis Factor-alphaTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.